Biofrontera (BFRI) Fundamentals 2026 — Revenue Analysis | SniperIQ
Biofrontera (BFRI) is a US-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Biofrontera's market cap?
Biofrontera (BFRI) has a market capitalization of approximately
What is Biofrontera's P/E ratio?
Biofrontera's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Biofrontera?
Biofrontera runs a net profit margin of -25.7%, a gross margin of 82.8%, and an operating margin of -20.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Biofrontera generate?
Biofrontera reported revenue of $42M for fiscal year 2025, with net income of -
Does Biofrontera pay a dividend?
Biofrontera does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Biofrontera financially healthy?
Biofrontera carries a debt-to-equity ratio of 1.27x and a current ratio of 1.20x, with a market beta of 0.82. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Biofrontera a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Biofrontera (BFRI) the key facts are: market cap
Track Biofrontera's full fundamentals live
Get Biofrontera's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.